- Home
- OCFT vs LPTX Comparison
OCFT vs LPTX Comparison
Compare OCFT & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCFT
- LPTX
- Stock Information
- Founded
- OCFT 2015
- LPTX 2011
- Country
- OCFT China
- LPTX United States
- Employees
- OCFT N/A
- LPTX N/A
- Industry
- OCFT Computer Software: Programming Data Processing
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OCFT Technology
- LPTX Health Care
- Exchange
- OCFT Nasdaq
- LPTX Nasdaq
- Market Cap
- OCFT 93.6M
- LPTX 91.8M
- IPO Year
- OCFT 2019
- LPTX N/A
- Fundamental
- Price
- OCFT $2.30
- LPTX $2.33
- Analyst Decision
- OCFT Strong Buy
- LPTX Strong Buy
- Analyst Count
- OCFT 1
- LPTX 5
- Target Price
- OCFT $7.00
- LPTX $10.40
- AVG Volume (30 Days)
- OCFT 333.2K
- LPTX 116.7K
- Earning Date
- OCFT 11-11-2024
- LPTX 11-11-2024
- Dividend Yield
- OCFT N/A
- LPTX N/A
- EPS Growth
- OCFT N/A
- LPTX N/A
- EPS
- OCFT N/A
- LPTX N/A
- Revenue
- OCFT $447,273,527.00
- LPTX N/A
- Revenue This Year
- OCFT N/A
- LPTX N/A
- Revenue Next Year
- OCFT N/A
- LPTX N/A
- P/E Ratio
- OCFT N/A
- LPTX N/A
- Revenue Growth
- OCFT N/A
- LPTX N/A
- 52 Week Low
- OCFT $0.87
- LPTX $1.31
- 52 Week High
- OCFT $4.98
- LPTX $5.00
- Technical
- Relative Strength Index (RSI)
- OCFT 50.07
- LPTX 40.85
- Support Level
- OCFT $2.20
- LPTX $2.20
- Resistance Level
- OCFT $4.98
- LPTX $2.45
- Average True Range (ATR)
- OCFT 0.62
- LPTX 0.16
- MACD
- OCFT -0.11
- LPTX -0.01
- Stochastic Oscillator
- OCFT 6.62
- LPTX 21.14
About OCFT OneConnect Financial Technology Co. Ltd.
OneConnect Financial Technology Co Ltd is a provider of technology platforms. Its platform provides cloud-native technology solutions that integrate financial services with market technology. The company offers technology applications and technology-enabled business services to financial institutions in China. Its technology solutions cover multiple verticals in the financial services industry, including banking, insurance and asset management, across the full scope of their businesses from sales and marketing and risk management to customer services and operations, as well as technology infrastructures such as data management and cloud services. The firm operates in two segments namely Technology Solutions which is the key revenue driver and Virtual Bank Business.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .